David Payne — CEO

David Payne is Vice President and Head of Infectious Diseases Research at GSK, where he leads a team focused on pioneering novel approaches to cure hepatitis B (HBV), viral, and bacterial infections. He is also responsible for supporting GSK’s portfolio of late-stage medicines for HBV, bacterial, and fungal infections. David leads GSK’s £45m partnership with the Fleming Initiative, which harnesses new technologies, including AI, to interpret complex scientific data and uncover opportunities for novel treatments and interventions to get ahead of drug-resistant infections. He has been an advisor to multiple government and non-government agencies on strategies to combat antimicrobial resistance (AMR), including contributing to President Obama’s report on AMR. He championed the integration of public-private partnerships as a solution to tackle AMR and currently serves as the Principal Investigator of GSK's BARDA (US HHS) contract, securing over $200M to share the risk and cost of progressing GSK's antibiotic portfolio. David is also a non-Executive Board Member of ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders. Throughout his career, David has demonstrated a strong commitment to translating scientific innovation into impactful treatments. He has successfully progressed multiple first in class medicines into clinical studies, including a first in a new class of antibiotics into Phase 3 trials and established a portfolio of therapeutics aimed at curing HBV. He further demonstrated his leadership by spearheading the creation of the GSK:Vir alliance during the SARS-CoV2 pandemic which delivered a therapeutic mAb from discovery to EUA approval in just 12 months. Prior to his current role, David served as Head of Medicine Opportunities, managing a diverse portfolio of high-value medicines in infectious diseases, COPD, Duchenne Muscular Dystrophy, and eye diseases. From 2017 to 2019, he was the Site Leader of GSK's US R&D hub in Upper Providence, Collegeville, PA. David is currently a board member of Life Sciences of PA and GSK’s US Charity Contributions Committee. He holds a PhD and DSc from The Medical School, University of Edinburgh, UK.

Stackforce AI infers this person is a leader in Healthcare, specializing in infectious diseases and antimicrobial resistance.

Location: Philadelphia, Pennsylvania, United States

Experience: 18 yrs 3 mos